Effect of estrogen-progestin and estrogen on mammographic density

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 52, Issue 6, 2007, Pages 513-520

  Kaewrudee, Srinaree ^a   Anuwutnavin, Sanitra ^a   Kanpittaya, Jaturat ^a   Soontrapa, Sugree ^a   Sakondhavat, Chuanchum ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Hormone replacement therapy; Mammographic breast density; Mammography; Postmenopause

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; BREAST CARCINOMA; COHORT ANALYSIS; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENOPAUSAL SYNDROME; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BREAST; COHORT STUDIES; DRUG COMBINATIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; THAILAND;

EID: 34250839985     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-1059
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
3. Writing Group for the Women's Health Initiative Investigators: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
4. Byrne C, Schairr C, Wolfe J, et al: Mammographic features and breast cancer risk: Effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622-1629
5. Byng JW, Yaffe MJ, Jong RA, et al: Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics 1998;18:1587-1598
6. Speroff L: The meaning of mammographic breast density in users of postmenopausal hormone therapy. Maturitas 2002;41:171-175
7. Evans A: Hormone replacement therapy and mammographic screening. Clin Radiol 2002;57:563-564
8. Kavanagh AM, Mitchell H, Giles GG: Hormone replacement therapy and accuracy of mammograghic screening. Lancet 2000;355:270-274
9. Greendale GA, Reboussin BA, Sie A, et al: Effects of estrogen and estrogen-progestin on mammographic parenchymal density: Postmenopausal estrogen/progestin intervention (PEPI) investigators. Ann Intern Med 1999;130:262-269
10. Ozdemir A, Konus A, Nas T, et al: Mammographic and ultrasonographic study of changes in breast related to HRT. Int J Gynecol Obstet1999;67:23-32
11. Sendag F, Cosen Terek MC, Ozsener S, et al: Mammographic density changes during different postmenopausal hormone replacement therapy. Fertil Steril 2001;76:445-450
12. Colacurci N, Fornaro F, de Franciscis P, et al: Effects of difference types of hormone replacement therapy on mammographic density. Maturitas 2001;40:159-164
13. Bulbul NH, Ozden S, Dayicioglu V: Effects of hormone replacement therapy on mammographic findings. Arch Gynecol Obstet 2003;268:5-8
14. Thaipisuttikul O, Tiawirat S, Janothan Y, et al: Effects of estrogen and estrogen-progestin replacement regimens on mammographic parenchymal density. Vajira Med J 2000;44: 199-206
15. Seukwattana S, Pongpatiroj A, Thaipisuttikul O, et al: Mammographic density changes of postmenopausal women after hormonal replacement therapy with cyclic and continuous combined regimens. Vajira Med J 2002; 46:241-248
16. Panpanit A, Muttarak M, Pongsatha S, et al: Mammographic change in hysterectomized women on 0.625 mg/day of conjugated equine estrogen. J Med Assoc Thai 2004;87:126-130
17. Srivatanakul P, Deerarasmee S, Feray J: Comparison of cancer incidence in Thailand with that in other countries. In Cancer in Thailand. Second volume, 1992-1994. Edited by S Deerarasmee, N Martin, S Sontipong. Lyon, International Academy of Research on Cancer, 1999 pp 93-95
18. American College of Radiology: Breast Imaging Reporting and Data System (BI-RADS). Second edition. Reston, VA, ACOR, 1995
19. Fiorica JV: Mammographic breast density and hormone replacement therapy (letter). Menopausal Med 2002;10:1-5
20. Prevrhal S, Shepherd JA, Smith-Bindman R, et al: Accuracy of mammographic breast density analysis: Results of formal operator training. Cancer Epidemiol Biomarkers Prev 2002; 11:1389-1393
21. Byrne C, Schairer C, Brinton LA, et al: Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control 2001;12:103-110
22. Clarke CL, Sutherland RL: Progestin regulation of cellular proliferation. Endocrinol Rev 1990;11:266-301
23. Longacre TA, Bartow SA: A correlative morphologic study of the human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-393
24. Modena MG, Sismondi P, Mueck AO, et al: New evidence regarding hormone replacement therapies is urgently required: Transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas 2005;52:1-10
25. Malet C, Spritzer P, Guillaumin D, et al: Progesterone effect on cell growth, ultrastructural aspect and estradiol receptors of normal human breast epithelial (HBE) cells in culture. J Steroid Biochem Mol Biol 2000;73:171-181
26. Pollow K, Boquoi E, Baumann J, et al: Comparison of the in vitro conversion of estradiol-17 beta to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 1977;6:333-348
27. Fournier S, Kuttenn F, de Cicco F, et al: Estradiol 17 beta-hydroxysteroid dehydrogenase activity in human breast fibroadenomas. J Clin Endocrinol Metab 1982;55:428-433
28. Coldham NG, James VH: A possible mechanism for increased breast cell proliferation by progestins through increased reductive 17 beta-hydroxysteroid dehydrogenase activity. Int J Cancer 1990;45:174-178
29. Udoff L, Langenberg P, Adashi EY: Combined continuous hormone replacement therapy: A clinical review. Obstet Gynecol 1995;86:306-316
30. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427
31. Hofseth LJ, Raafat AM, Osuch JR, et al: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565
32. Foidart JM, Colin C, Denoo X, et al: Estradiol and progesterone regulate the proliferation of human breast epithelial cells. Fertil Steril 1998;69:963-969
33. De Lignieres B, de Vathaire F, Fournier S, et al: Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women. Climacteric 2002;5:332-340
34. Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-454
35. Christodoulakos GE, Lambrinoudaki IV, Panoulis KP, et al: The effect of various regimens of hormone replacement therapy on mammographic breast density. Maturitas 2003;45: 109-118
36. Chetrite G, Kloosterboer HJ, Pasqualini JR: Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 1997;17:135-140
37. Kloosterboer HJ, Schoonen WG, Deckers GH, et al: Effects of progestogens and Org OD 14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994;49:311-318
38. Lundstrom E, Christow A, Kersemaekers W, et al: Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186;717-722
39. Kerlikowske K, Shepherd J, Creasman J, et al: Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 2005;97:368-374